Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096144 · ClinicalTrials.gov registry record · Phase 3
Comparison of Sugammadex and Neostigmine During PACU Stay
A Phase 3 study, sponsored by University of South Florida.
- Not yet
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT04096144 is a Phase 3 study that has not yet begun recruiting, run by University of South Florida. The registered enrollment target is 50 participants.
The verdict
NCT04096144, a Phase 3 study, has not yet begun recruiting, sponsored by University of South Florida.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
Sugammadex was approved for post-operative use in the operating room (OR) and post-anesthesia recovery unit (PACU) of our quaternary facility, Tampa General Hospital. The approval came with administrative limitations: 2mg/kg dose only and for the first year its utilization was limited as replacement for up to half of Neostigmine/Glycopyrrolate use. An MUE evaluation was completed for a retrospective chart review from March 2017 to December 2017 (10 months) to assess all cases in which patients received Sugammadex or Neostigmine. During the year of data collection, we also noted a widespread tendency to reduce the usage of narcotics. A t-test comparison of the length of stay (LOS) in the PACU revealed a highly significant difference between the LOS in PACU for both drugs. On average, patients receiving Sugammadex were discharged from the PACU 43 minutes earlier than patients who received Neostigmine/Glycopyrrolate. The patient mix in both groups was similar, but these data were obtained retrospectively by a pharmacy chart review.
Interventions
- DRUG Neuromuscular Blocking Agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2020-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096144
The ClinicalTrials.gov registry entry for NCT04096144 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neuromuscular Blocking Agents is the first listed.
NCT04096144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04096144 about?
NCT04096144 is a clinical study titled "Comparison of Sugammadex and Neostigmine During PACU Stay". Sugammadex was approved for post-operative use in the operating room (OR) and post-anesthesia recovery unit (PACU) of our quaternary facility, Tampa General Hospital. The approval came with administrative limitations: 2mg/kg dose only and for the first year its utilization was limited as replacement...
What is the current status of trial NCT04096144?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2019-10-15. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT04096144?
The interventions under investigation include: Neuromuscular Blocking Agents (DRUG).
Who is sponsoring clinical trial NCT04096144?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.